Download MendeleyA conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation.
Bahar, M.W., Nasta, V., Fox, H., Sherry, L., Grehan, K., Porta, C., Macadam, A.J., Stonehouse, N.J., Rowlands, D.J., Fry, E.E., Stuart, D.I.(2022) Commun Biol 5: 1293-1293
- PubMed: 36434067
- DOI: https://doi.org/10.1038/s42003-022-04252-5
- Primary Citation of Related Structures:
8AYX, 8AYY, 8AYZ - PubMed Abstract:
Strategies to prevent the recurrence of poliovirus (PV) after eradication may utilise non-infectious, recombinant virus-like particle (VLP) vaccines. Despite clear advantages over inactivated or attenuated virus vaccines, instability of VLPs can compromise their immunogenicity. Glutathione (GSH), an important cellular reducing agent, is a crucial co-factor for the morphogenesis of enteroviruses, including PV. We report cryo-EM structures of GSH bound to PV serotype 3 VLPs showing that it can enhance particle stability. GSH binds the positively charged pocket at the interprotomer interface shown recently to bind GSH in enterovirus F3 and putative antiviral benzene sulphonamide compounds in other enteroviruses. We show, using high-resolution cryo-EM, the binding of a benzene sulphonamide compound with a PV serotype 2 VLP, consistent with antiviral activity through over-stabilizing the interprotomer pocket, preventing the capsid rearrangements necessary for viral infection. Collectively, these results suggest GSH or an analogous tight-binding antiviral offers the potential for stabilizing VLP vaccines.
Organizational Affiliation:
Division of Structural Biology, University of Oxford, The Henry Wellcome Building for Genomic Medicine, Headington, Oxford, OX3 7BN, UK. mohammad.bahar@strubi.ox.ac.uk.
